. 2022 Nov;29(6):985-992.

doi: 10.1007/s12282-022-01378-6. Epub 2022 Jun 22.

Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan

Akihiko Shimomura¹, Masayuki Nagahashi², Hiraku Kumamaru^{3

4}, Kenjiro Aogi⁵, Sota Asaga⁶, Naoki Hayashi⁷, Kotaro Iijima⁸, Takayuki Kadoya⁹, Yasuyuki Kojima¹⁰, Makoto Kubo¹¹, Minoru Miyashita¹², Hiroaki Miyata^{4

13}, Naoki Niikura¹⁴, Etsuyo Ogo¹⁵, Kenji Tamura¹⁶, Kenta Tanakura¹⁷, Masayuki Yoshida¹⁸, Yutaka Yamamoto¹⁹, Shigeru Imoto⁶, Hiromitsu Jinno²⁰

Affiliations

¹ Department of Breast and Medical Oncology, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan. akshimomura@hosp.ncgm.go.jp.
² Department of Breast and Endocrine Surgery, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya-shi, Hyogo, 663-8501, Japan.
³ Department of Healthcare Quality Assessment, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
⁴ National Clinical Database, Tokyo, Japan.
⁵ Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Kou 160, Minamiumemotomachi, Matsuyama-shi, Ehime, 791-0280, Japan.
⁶ Department of Breast Surgery, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, 181-8611, Japan.
⁷ Department of Breast Surgical Oncology, St. Luke's International Hospital, 9-1 Akashicho, Chuo-ku, Tokyo, 104-8560, Japan.
⁸ Department of Breast Oncology, Juntendo University, 3-1-3 Hongo, Bunkyo-ku, Tokyo, 113-8431, Japan.
⁹ Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-0037, Japan.
¹⁰ Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki-shi, Kanagawa, 216-8511, Japan.
¹¹ Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka-shi, Fukuoka, 812-8582, Japan.
¹² Department of Breast and Endocrine Surgical Oncology, Tohoku University School of Medicine, Seiryo-machi, Aoba-ku, Sendai-shi, Miyagi, 980-8574, Japan.
¹³ Department of Health Policy and Management, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
¹⁴ Department of Breast Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara-shi, Kanagawa, 259-1193, Japan.
¹⁵ Department of Radiology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume-shi, Fukuoka, 830-0011, Japan.
¹⁶ Department of Medical Oncology, Shimane University Hospital, Shimane, Japan.
¹⁷ Division of Plastic and Reconstructive Surgery, Mitsui Memorial Hospital, 1 Kanda-Izumi-cho, Chiyoda-ku, Tokyo, 101-8643, Japan.
¹⁸ Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
¹⁹ Department of Breast and Endocrine Surgery, Kumamoto University Hospital, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, Kumamoto, 860-8556, Japan.
²⁰ Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8606, Japan.

PMID: 35733033
PMCID: PMC9587939
DOI: 10.1007/s12282-022-01378-6

Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan

Akihiko Shimomura et al. Breast Cancer. 2022 Nov.

. 2022 Nov;29(6):985-992.

doi: 10.1007/s12282-022-01378-6. Epub 2022 Jun 22.

Authors

Affiliations

¹ Department of Breast and Medical Oncology, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan. akshimomura@hosp.ncgm.go.jp.
² Department of Breast and Endocrine Surgery, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya-shi, Hyogo, 663-8501, Japan.
³ Department of Healthcare Quality Assessment, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
⁴ National Clinical Database, Tokyo, Japan.
⁵ Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Kou 160, Minamiumemotomachi, Matsuyama-shi, Ehime, 791-0280, Japan.
⁶ Department of Breast Surgery, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, 181-8611, Japan.
⁷ Department of Breast Surgical Oncology, St. Luke's International Hospital, 9-1 Akashicho, Chuo-ku, Tokyo, 104-8560, Japan.
⁸ Department of Breast Oncology, Juntendo University, 3-1-3 Hongo, Bunkyo-ku, Tokyo, 113-8431, Japan.
⁹ Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-0037, Japan.
¹⁰ Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki-shi, Kanagawa, 216-8511, Japan.
¹¹ Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka-shi, Fukuoka, 812-8582, Japan.
¹² Department of Breast and Endocrine Surgical Oncology, Tohoku University School of Medicine, Seiryo-machi, Aoba-ku, Sendai-shi, Miyagi, 980-8574, Japan.
¹³ Department of Health Policy and Management, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
¹⁴ Department of Breast Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara-shi, Kanagawa, 259-1193, Japan.
¹⁵ Department of Radiology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume-shi, Fukuoka, 830-0011, Japan.
¹⁶ Department of Medical Oncology, Shimane University Hospital, Shimane, Japan.
¹⁷ Division of Plastic and Reconstructive Surgery, Mitsui Memorial Hospital, 1 Kanda-Izumi-cho, Chiyoda-ku, Tokyo, 101-8643, Japan.
¹⁸ Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
¹⁹ Department of Breast and Endocrine Surgery, Kumamoto University Hospital, 1-1-1 Honjo, Chuo-ku, Kumamoto-shi, Kumamoto, 860-8556, Japan.
²⁰ Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8606, Japan.

PMID: 35733033
PMCID: PMC9587939
DOI: 10.1007/s12282-022-01378-6

Abstract

Background: Male breast cancer (MBC) is rare; however, its incidence is increasing. There have been no large-scale reports on the clinicopathological characteristics of MBC in Japan.

Methods: We investigated patients diagnosed with breast cancer in the Japanese National Clinical Database (NCD) between January 2012 and December 2018.

Results: A total of 594,316 cases of breast cancer, including 3780 MBC (0.6%) and 590,536 female breast cancer (FBC) (99.4%), were evaluated. The median age at MBC and FBC diagnosis was 71 (45-86, 5-95%) and 60 years (39-83) (p < 0.001), respectively. MBC cases had a higher clinical stage than FBC cases: 7.4 vs. 13.3% stage 0, 37.2 vs. 44.3% stage I, 25.6 vs. 23.9% stage IIA, 8.8 vs. 8.4% stage IIB, 1.9 vs. 2.4% stage IIIA, 10.1 vs. 3.3% stage IIIB, and 1.1 vs. 1.3% stage IIIC (p < 0.001). Breast-conserving surgery was more frequent in FBC (14.6 vs. 46.7%, p = 0.02). Axillary lymph node dissection was more frequent in MBC cases (32.9 vs. 25.2%, p < 0.001). Estrogen receptor(ER)-positive disease was observed in 95.6% of MBC and 85.3% of FBC cases (p < 0.001). The HER2-positive disease rates were 9.5% and 15.7%, respectively (p < 0.001). Comorbidities were more frequent in MBC (57.3 vs. 32.8%) (p < 0.001). Chemotherapy was less common in MBC, while endocrine therapy use was similar in ER-positive MBC and FBC. Perioperative radiation therapy was performed in 14.3% and 44.3% of cases.

Conclusion: Japanese MBC had an older age of onset, were more likely to be hormone receptor-positive disease, and received less perioperative chemotherapy than FBC.

Keywords: Japanese; Male breast cancer; National clinical database.

PubMed Disclaimer

Conflict of interest statement

Dr. Shimomura reports grants and personal fees from Chugai Pharmaceutical, grants and personal fees from AstraZeneca, grants and personal fees from Daiichi Sankyo, grants and personal fees from EISAI, grants from Taiho Pharmaceutical, grants from Mochida Pharmaceutical, personal fees from Pfizer, personal fees from Novartis, personal fees from Eli-Lilly, personal fees from Kyowa Kirin, personal fees from Takeda Pharmaceutical, and personal fees from MSD outside the submitted work. Dr. Kumamaru reports consulting fees from Mitsubishi-Tanabe Pharma, personal fees from Johnson and Johnson, personal feesl from Pfizer, personal fees from Chugai Pharmaceutical outside the submitted work, affiliated with the department of Healthcare Quality Assessment at the University of Tokyo supported by National Clinical Dabatase, Johnson & Johnson, and Nipro. Dr. Hayashi reports personal fees from AstraZeneca, personal fees from Taiho Pharmaceutical, personal fees from EISAI, personal fees from Exact Science, personal fees from Eli-Lilly, personal fees from Daiichi Sankyo, personal fees from Novartis, personal fees from Pfizer, personal fees from Chugai Pharmaceutical outside the submitted work. Dr. Miyata reports grants from affiliation of social collaboration department of National Clinical Database, Johnson and Johnson, and Nipro. Dr. Yamamoto reports personal fees from AstraZeneca, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Kyowa Kirin, personal fees from Novartis, grants and personal fees from EISAI, grants and personal fees from Daiichi Sankyo, grants and personal fees from Nippon Kayaku, grants and personal fees from Taiho Pharmaceutical, grants and personal fees from Takeda, grants and personal fees from Eli-Lilly, grants and personal fees from Pfizer, personal fees from Taiho Pharmaceutical, personal fees from Sysmex, personal fees from MSD outside the submitted work. Dr. Imoto reports grants from Taiho Pharmaceutical, grants from Daiichi Sankyo, grants from Eli-Lilly outside the submitted work. The other authors declare no potential conflicts of interest.

Figures

**Fig. 1**
Distribution of each subtype in MBC (a) and FBC (b)

See this image and copyright information in PMC

References

1. Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan (Vital Statistics of Japan). 2020.
1. Hayashi N, Kumamaru H, Isozumi U, Aogi K, Asaga S, Iijima K, et al. Annual report of the Japanese Breast Cancer Registry for 2017. Breast Cancer. 2020;27:803–809. doi: 10.1007/s12282-020-01139-3. - DOI - PubMed
1. Ministry of Health LaW. Abridged life table. 2019; 2021.
1. Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018;29:405–417. doi: 10.1093/annonc/mdx651. - DOI - PMC - PubMed
1. Miyata H, Gotoh M, Hashimoto H, Motomura N, Murakami A, Tomotaki A, et al. Challenges and prospects of a clinical database linked to the board certification system. Surg Today. 2014;44:1991–1999. doi: 10.1007/s00595-013-0802-3. - DOI - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

KAKENHI (JP19K16880)/Japan Society for the Promotion of Sciences

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan

Affiliations

Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous